摘要:
It is intended to provide heteroaryl 5-thio-beta-D-glucopyranoside compounds represented by the following general formula which show an effect of inhibiting the activity of SGLT2, pharmaceutically acceptable salts thereof or hydrates of the same; and drugs containing the same as the active ingredient, in particular, remedies for diabetes, diabetes-related diseases or complications of diabetes.
摘要:
It is intended to provide 5-thio-beta-D-glucopyranoside compounds represented by the following general formula (i), which show an effect of inhibiting the SGLT2 activity, pharmaceutically acceptable salts thereof or hydrates of the same; and drugs (in particular, preventives or remedies for diabetes, diseases relating to diabetes or diabetic complications) containing the same as the active ingredient: (i)
摘要:
Aminobenzoic acid derivatives represented by general formula (1) or pharmaceutically acceptable salts thereof which are usable as VEGF receptor antagonists, in particular, remedies for diseases in which VEGF participates wherein R1 represents hydrogen, C¿1-6? alkyl, etc.; R?2¿ represents hydrogen, C¿1-6? alkyl, etc.; R?3¿ represents C¿8-25? alkyl, etc.; R?4¿ represents hydrogen, OR9 or CO¿2R?10 (wherein R?9 and R10¿ represent each hydrogen or C¿1-6? alkyl); A represents S(O)qR?15¿ [wherein q is 0, 1 or 2; and R15 represents C¿1-6? alkyl, phenyl (C1-3 alkyl) or (CH2)mOR?16¿ (wherein m is 2 or 3; and R16 represents hydrogen or methoxymethyl)], etc.; X represents O, a single bond, CH=CH or NR27 (wherein R27 represents hydrogen or t-butoxycarbonyl); Y represents O, CONH, NHCO or NR28 (wherein R28 represents hydrogen or t-butoxycarbonyl); and n is an integer of from 0 to 15.
摘要翻译:式(1)表示的氨基苯甲酸衍生物如下:(其中,R 1表示氢原子,C 1-6烷基等; R 2表示氢原子, 6烷基等; R 3表示C8-25烷基等; R 4表示氢原子或由OR 9或CO 2 R 10表示的基团(其中R“ 9>和R 10表示氢原子或C 1-6烷基); A表示由S(O)q R 15表示的基团(其中q为0,1或2,R 15表示 C 1-6烷基,苯基C 1-3烷基或由(CH 2)mOR 16表示的基团(其中m为2或3,R 16表示氢原子或甲氧基甲基), X表示O,单键,CH = CH或由NR 27表示的基团(其中R 27表示氢原子或叔丁氧基羰基); Y表示O,CONH,NHCO 或由NR 28表示的基团(其中R 28表示氢原子或叔丁氧基羰基); n为0〜15的整数) 或其药学上可接受的盐用作VEGF受体拮抗剂,特别是作为涉及VEGF的疾病的治疗剂。
摘要:
A quinolinecarboxylic acid represented by general formula (C) or a medicinally acceptable salt thereof, each having a serotonergic receptor-stimulating effect on sertonin 4 receptors. In said formula, C represents hydroxymethyl, methoxy, ethoxy or morpholinyl. Therefore they have the effect of activating digestive motion and are efficacious in ameliorating chronic gastritis, diabetes and various diseases accompanying the lowering of stomach motility and gastric excretory function after gastrectomy, such as heartburn, anorexia, epigastralgia and abdominal swelling, and in treating reflux esophagitis, false ileus and constipation.
摘要:
Endo-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl) 1-isopropyl-2(1H)-quinolone-3-carboxylate represented by formula (1) or an acid-addition salt thereof, acting on serotonin 4 receptors to exhibit a serotonin-like receptor-stimulating effects. Therefore the compound has the activity of activating digestive tract movement and is efficacious in ameliorating digestive symptoms accompanying chronic gastritis, postgastrectomy syndrome and so forth, such as pyrosis, anorexia, epigastralgia or abdominal distension, and in treating reflux esophagitis, pseudoileus and constipation.